Receive our newsletter – data, insights and analysis delivered to you
  1. Clinical Trials Analysis
February 19, 2021

North America accounts for 22.5% share of global clinical trial activity in 2020

North America accounted for a 22.5% share of global clinical trials activity in 2020, a decrease of 5.7% compared with a 28.2% average over the last ten-years, according to GlobalData.

In North America, single country studies held a 76.9% share for all clinical trials in 2020, compared with the ten-year average of 76.6%. Multinational trials accounted for a 23.1% share in 2020 against an average of 23.4% in the last ten years.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

Industry sponsored trials outnumber non-industry sponsored trials in North America

Industry sponsored trials held a 62.4% share of all the clinical trials in North America in 2020, a rise over their ten-year average of 61.8%. Non-industry sponsored trials accounted for a 37.6% share in 2020, down from an average of 38.2% in the last ten years.

Content from our partners
The importance of reference products in biosimilar trials, and how to source them
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

2020 industry sponsored clinical trials in North America – Top therapy areas

Oncology was the leading therapy area for industry sponsored clinical trials in North America in 2020 with a 34.2% share, up from its ten-year average of 31.9%.

Infectious Disease held a 19.2% share in 2020, up from its ten-year average of 10.1%.

In the third place was Central Nervous System with a 12.7% share in 2020, down from its ten-year average of 15.8%. Respiratory recorded a 7.7% share in 2020, a rise over its ten-year average of 4.8%.

With a share of 5.7% in 2020, Metabolic Disorders down from its ten-year average of 8.2%.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

Non-industry sponsored clinical trials in North America by top therapy areas

Oncology was the leading therapy area for non-industry sponsored clinical trials in North America in 2020 with a 29.5% share, on par with the ten-year average of 29.4%.

In the second place was Central Nervous System with a 23.6% share in 2020, which represented a drop over a ten-year average of 28.9%.

With a share of 21.7% in 2020, Infectious Disease witnessed a large rise over its ten-year average of 9.1%. Cardiovascular held an 8.2% share in 2020, against a ten-year average of 8.9%.

Respiratory held a 6.8% share, which was up from the ten-year average of 4.3%.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

2020 clinical trials in North America by phase

In terms of phases, Phase II trials led the industry sponsored clinical trials in North America in 2020, with a share of 43.8%, marking a rise over a ten-year average of 40.7%.

Phase I trials stood next with a 26.2% share in 2020, which was very slightly down against a ten-year average of 26.6%.

In the third place was Phase III trials with a 23.3% share in 2020, just up from its ten-year average of 23.0%.

Phase IV trials held an 6.7% share in 2020, with a 3.1% drop over its ten-year average of 9.8%.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

 

For non-industry sponsored clinical trials in North America, Phase II trials held a leading share of 49.7% in 2020, on par with its ten-year average of 49.6%.

In second place was Phase I trials that held a 21.3% share in 2020, remaining flat over its ten-year average of 21.3%.

Phase IV trials stood at 16.4% share, as against ten-year average of 19.1%.

Phase III trials held a 12.7% share in 2020, up from its ten-year average of 10.1%.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

 

Methodology:
The clinical trials data used for the analyses were extracted from the Clinical Trials Database of GlobalData’s Pharma Intelligence Center. Clinical Trials are sourced from numerous government, non-government and company clinical trial registries worldwide alongside clinical research publications, scientific conferences, company websites, SEC filings and more. The information is gathered by a combination of automation and secondary research to ensure accuracy and validity. A small number of Phase 0, Phase I/II, Phase II/III, and Phase III/IV trials were combined with Phase I, Phase II, Phase III, and Phase IV trials, respectively.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU